CannTrust recently announced an enhancement of their partnership with generic-drug giant Apotex. Business of Cannabis connected with CannTrust President Brad Rogers to talk about what this partnership, along with supply agreements in BC, Manitoba and Alberta mean for CannTrust and the future of cannabis in Canada.
Why Reading Research MattersThe volume of cannabis research has never been higher, but not all studies are created equal. Every...
First published on Cannabis Health Medical cannabis patients made history in London with a first-of-its-kind, patient-led education event focused on...
Curaleaf Laboratories, one of the UK’s leading providers of medicinal cannabis products, is pleased to announce a landmark partnership with...
Cookies, the most globally recognised cannabis brand, is entering global medical markets with a full extract portfolio through a strategic...
Sorting Evidence from Anecdote As global cannabis research accelerates, the number of published studies has never been higher, but not...
Cannim Group Pty, the international medical cannabis company with operations spanning the UK, Australia, the US and Canada, has entered...
Despite being the second-largest and one of the most mature medical cannabis markets in Europe, the UK still falls well...
Cannabis is now one of the most frequently discussed therapeutic agents in modern medicine, driven by expanding access programmes and...
The European medical cannabis industry is continuing to mature, seeing companies focused on science-based research push the boundaries of our...
Industry leaders, regulators and investors meet at Business of Cannabis New York to discuss funding, regulation and sustainable market growth.
The Advisory Council on the Misuse of Drugs (ACMD) has closed its latest call for evidence into the impact of...
The Czech Republic, long considered one of Europe’s most progressive countries on cannabis and wider drug reform, is entering a...
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
